User profiles for Michèle Tameris
Michele TamerisSATVI University of Cape Town Verified email at uct.ac.za Cited by 7250 |
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial
…, ST Malherbe, R Hassan-Moosa, M Tameris… - The Lancet Infectious …, 2021 - thelancet.com
Background Targeted preventive therapy for individuals at highest risk of incident tuberculosis
might impact the epidemic by interrupting transmission. We tested performance of a …
might impact the epidemic by interrupting transmission. We tested performance of a …
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study
…, ST Malherbe, R Hassan-Moosa, M Tameris… - The Lancet Global …, 2021 - thelancet.com
Background A rapid, blood-based triage test that allows targeted investigation for tuberculosis
at the point of care could shorten the time to tuberculosis treatment and reduce mortality. …
at the point of care could shorten the time to tuberculosis treatment and reduce mortality. …
[HTML][HTML] Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
MD Tameris, M Hatherill, BS Landry, TJ Scriba… - The Lancet, 2013 - thelancet.com
Background BCG vaccination provides incomplete protection against tuberculosis in infants.
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …
A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was …
Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
…, V Nduba, TG Pascal, M Tameris… - … England Journal of …, 2019 - Mass Medical Soc
Background Results of an earlier analysis of a trial of the M72/AS01 E candidate vaccine
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% …
against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% …
Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis
…, GL Blatner, MA Demoitié, M Tameris… - … England Journal of …, 2018 - Mass Medical Soc
Background A vaccine to interrupt the transmission of tuberculosis is needed. Methods We
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E …
conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 E …
The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults
B Abel, M Tameris, N Mansoor… - American journal of …, 2010 - atsjournals.org
Rationale: AERAS-402 is a novel tuberculosis vaccine designed to boost immunity primed by
bacillus Calmette-Guérin (BCG), the only licensed vaccine. Objectives: We investigated the …
bacillus Calmette-Guérin (BCG), the only licensed vaccine. Objectives: We investigated the …
Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
Modified vaccinia Ankara‐expressing Ag85A (MVA85A) is a new tuberculosis (TB) vaccine
aimed at enhancing immunity induced by BCG. We investigated the safety and …
aimed at enhancing immunity induced by BCG. We investigated the safety and …
T-cell activation is an immune correlate of risk in BCG vaccinated infants
…, M Hatherill, G Hussey, H Mahomed, M Tameris… - Nature …, 2016 - nature.com
Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case–control
analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin (…
analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin (…
Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR
…, K Hadley, M Erasmus, O Nombida, M Tameris… - Communications …, 2022 - nature.com
Background Sensitive point-of-care screening tests are urgently needed to identify
individuals at highest risk of tuberculosis. We prospectively tested performance of host-blood …
individuals at highest risk of tuberculosis. We prospectively tested performance of host-blood …